Comparison · NCT02807857-sae
Enrolled Set vs Follow-Up Set: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Enrolled Set vs Follow-Up Set: serious adverse events. Trial comparisons, record NCT02807857-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02807857-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0827 | 0.0694 | 0.0982 | wilson | |
| Risk in group 2 | 0.132 | 0.111 | 0.157 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0497 | -0.0774 | -0.0236 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.624 | 0.489 | 0.797 | log | |
| Odds ratio, group 1 over group 2 | 0.591 | 0.449 | 0.776 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Enrolled Set than on Follow-Up Set | 20.1 | 12.9 | 42.4 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Enrolled Set | Adult male and female patients with chronic heart failure with reduced ejection fraction (LVEF ≤ 40%) who were managed in a primary care setting in sites across Europe. | 117 | 1,415 | EG000 |
| Group 2 | Follow-Up Set | Patients who were considered clinically stable and with NT-proBNP levels \> 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set. | 114 | 861 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse Events were collected from FPFV to LPLV up to 2 years.
Source ClinicalTrials.gov
Trial
- Title
- A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care
- NCT number
- NCT02807857
- Phases
- NA
- Conditions
- Chronic Heart Failure (CHF)
- Interventions
- Standard care
- Lead sponsor
- Novartis Pharmaceuticals
- Results first posted
- 2021-01-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02807857?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02807857-sae